CD177 and prostate carcinoma: It has emerged as a beneficial radioligand target in prostate cancer treatment due to its limited expression in normal tissue, high expression levels on the plasma membrane of the tumor cell, function as an internalizing cell surface receptor [9], and increased expression with androgen deprivation therapy (ADT) [10].